Purpose Increasing numbers of haematology cancer survivors warrants identification of the most effective model of survivorship care to survivors from a diverse range of haematological cancers with aggressive treatment regimens. This review aimed to identify models of survivorship care to support the needs of haematology cancer survivors. Method An integrative literature review method utilised a search of electronic databases (CINAHL, Medline, PsycInfo, PubMed, EMBASE, PsycArticles, and Cochrane Library) for eligible articles (up to July 2014). Articles were included if they proposed or reported the use of a model of care for haematology cancer survivors. Results Fourteen articles were included in this review. Eight articles proposed and described models of care, and six reported the use of a range of survivorship models of care in haematology cancer survivors. No randomised controlled trials or literature reviews were found to have been undertaken specifically with this cohort of cancer survivors. There was variation in the models described and who provided the survivorship care. Conclusion Due to the lack of studies evaluating the effectiveness of models of care, it is difficult to determine the best model of care for haematology cancer survivors. Many different models of care are being put into practice before robust research is conducted. Therefore, well-designed high-quality pragmatic randomised controlled trials are required to inform clinical practice.
Introduction
Internationally, survivorship care is recognised as a priority in the cancer care continuum. This has been principally guided by the Institute of Medicine (IOM) report in 2005, From Cancer Patient to Cancer Survivor: Lost in Transition [1] . By 2008, 16 European countries had defined national cancer plans, but to date, very few have survivorship services operating [2] . The National Coalition for Cancer Survivorship [3] defines survivorship as the experience of living with, through, and beyond a diagnosis of cancer and includes the impact on family, friends, and caregivers. It is recognised throughout the literature, based on the IOM essential components of survivorship care, that survivorship care should include the following components [4, 5] : & Prevention; screening and interventions for recurrence, long-term and late effects; early detection of new cancers; & Assessment, support, management, and information provision of physical, psychological, social, and spiritual needs; & Monitoring, information, and promotion of healthy living behaviours and disease prevention; and & Coordination of care between providers to communicate overall health needs.
Current conventional models of survivorship care, including routine follow-up, predominately focus on surveillance for recurrence and monitoring of physical side effects, rather than provision of supportive care, health promotion, late effects monitoring, and surveillance for new cancers [6, 7] . With an increasing awareness that communication between health care professionals and patients is suboptimal and that information provided to patients and primary care providers at treatment completion is often inadequate [8, 9] , there is a growing movement to redesign how survivorship follow-up care is delivered. Furthermore, cancer patients frequently experience multiple health problems earlier than the general population [10] , suggesting a need for early and ongoing, comprehensive approaches to management designed to promote and support patient participation in maximising recovery.
Haematology cancer patients are underrepresented and understudied in survivorship care [11] despite international figures indicating an increase in 5-year relative survival rates [12] . The most common haematological cancers are leukaemias, lymphomas, and multiple myelomas (MM) [13] . Each of these has distinctive and complex treatment regimens that commonly involve aggressive high-dose chemotherapy agents, and/or targeted therapies, radiotherapy, and haematopoietic stem cell transplants [14] . Unfortunately, the consequence of largely aggressive treatment includes longterm and late physical, practical, and psychosocial effects which include fear of recurrence, fertility, relationship, financial, employment, and insurance issues [15] [16] [17] . A qualitative study on specialist-led follow-up with haematology cancer survivors reported a lack of preparation and support in finding information and resources with poor continuity of care as patients transitioned into the survivorship phase [18] . These patients, therefore, may require models of survivorship care with specific components that differ from those designed for the more common cancers (breast, prostate, and colorectal).
Two systematic reviews [19, 20] and a literature review [6] on survivorship models of care have been recently published. Sussman et al. [20] reviewed 12 randomised controlled trials (RCTs) and four systematic reviews. De Leeuw and Larsson [6] reviewed 21 nurse-led follow-up studies and Howell et al. [19] evaluated ten practice guidelines and nine RCTs. All primary outcomes in the reviewed studies were related to recurrence detection and in some cases health-related quality of life and/or patient satisfaction [6, 19, 20] . Importantly, all studies included cancers with similar trajectories of care (breast, prostate, and colon), making generalisations to other complex cancers such as haematological cancers difficult. Therefore, the haematology focus of this integrative literature review will add to the limited body of knowledge currently available in this cohort of survivors.
This integrative literature review undertook an analysis of the literature to examine the following questions:
(1). What are the common attributes of survivorship models of care developed generally for cancer patients and specifically for haematology cancer patients? (a). What resources (human, financial, tools, and care plans) are required to support these models of care? (b). What are the potential benefits and shortfalls of these models of care? (c). What outcome measures have been used to evaluate these models of care and what are the findings?
Method
The integrative literature review method was chosen as the theoretical framework to guide this review. It is structured according to five stages: problem formulation, literature search, data evaluation, data analysis, and presentation. This allows for an in-depth evaluation of the issues encompassing the empirical, theoretical, and clinical approaches within a structured systematic methodology [21] .
Problem formulation
To date, the term 'Model of Care' (MOC) has not been well defined in published literature. In this review, MOC, as defined by the Robert Wood Johnson Foundation [22] , is a conceptual outline of how to plan all current and future facility and clinical services to guide and direct a patient's experience within a health care system. Essential elements of any MOC include a clear identification of health professionals responsible for planning and coordination of care, care delivery setting [20] , promotion of health maintenance, effective illness interventions, and establishing and evaluating expected clinical outcomes [23] . The medical specialist has traditionally led haematology cancer care follow-up; however, other models of cancer survivorship follow-up are now emerging [24] . Therefore, the focus of this integrative literature review was to identify models of care used by health care providers to ensure quality survivorship follow-up for haematology cancer survivors. Table 1 . Due to variations in study population and methodologies used, meta-analysis was not possible.
Results

Study characteristics
No systematic reviews of haematology cancer survivorship models of care were found. In total, 14 articles were included in this review. Eight articles described and proposed different models of survivorship care [27, 28, 1, 5, 29, 30, 9, 7] ( Table 2 ). An additional six articles reported the use of a range of models of care for haematology cancer survivors: two reported nurse-led studies [31, 32] and four referred to physician-led studies [33, 8, 34, 35] (Table 3 ). The included articles reported views from Australia (n=1), the US (n=10), and the UK (n=3) shown in Table 3 . The eight articles that described and proposed various models of survivorship care were categorised into three main settings hospital-based, primary care-based, and shared care and included models, providers, and characteristics. The results are shown in Table 2 . These included articles used multiple terms to describe clinicians. For clarity, the following terms have been used: primary care provider (PCP) to denote community-based general practitioners (GP) or family physicians; specialist to represent the main hospital consultant oncologist (medical, radiation, and surgical) or haematologist; and nurse which includes nurse specialist, nurse practitioner (NP), or nurse coordinator.
Of the six studies that reported the use of specific models of survivorship care, four were quantitative and two were qualitative studies. Studies reflected moderate (IV) to low (VI) levels of evidence.
Data analysis and presentation
Cancer survivorship MOC
The first component of this integrative literature review was to identify different models of survivorship care (Table 2) . Characteristically, hospital-based follow-up care is commonly specialist-led, with often no end point [27, 29] . Survivors may acquire an impression the specialist has become their primary carer, particularly if they have assessed and treated co-morbid conditions during the treatment phase [7] . Multidisciplinary disease-specific clinics [5, 9, 7] and survivorship clinics were most often a one-time consultation for an assessment, plan of follow-up care provision and referrals to other health care providers [1, 30] . Clinics within this framework frequently consulted on one aspect of post-treatment care, such as late effects [9] . Nurse-led survivorship clinics, as described, were mostly hospital-based and delivered a number of interventions including information, symptom management, psychosocial support, allied health referrals, and health promotion strategies [27] . They can involve longer consultations and more frequent patient contact [27, 6] . PCP-led models involved a complete transition of all care from the hospital specialist to PCP [28, 5, 9] . This can be challenging for specialists who decide to transition care, as the level of knowledge and experience amongst PCPs can differ [5, 30] .
Shared care models involved more than two providers sharing care and responsibility [1, 9] . According to Oeffinger and McCabe [7] , after treatment completion, the PCP assumes responsibility for maintenance of survivor health, management of any co-morbid conditions, ongoing physical and psychosocial concerns, and health promotion. The medical specialist provides a survivorship care plan and treatment summary and ongoing consultation for recurrence or problematic late effects if required. Both providers are to undertake monitoring, therefore, a clear delineation of responsibility for particular screening and surveillance is important [5] . Landier [5] identified shared care as appropriate for low-risk and even some moderate-risk patients; however, intensively treated patients (i.e. haematological cancers) require specialist monitoring.
Nurse-led
The two studies that evaluated nurse-led follow-up in lymphoma survivors predominately targeted late effects and health promotion. Gates et al. [31] studied a nurse-led component of a haematology late effects survivorship multidisciplinary team, whereas John and Armes [32] reported on nurses replacing specialist-led follow-up, independently delivering comprehensive survivorship care. Both clinics assessed for supportive care needs and concerns and delivered health promotion and information [31, 32] . John and Armes [32] provided an annual clinic with nurse contact details, whereas Gates et al. [31] delivered four consultations over a 6-month period. Both studies measured different outcomes and utilised different comparative groups, thereby making them difficult to compare, especially as Gates et al. [31] have only published preliminary results. A prospective comparative study of 61 patients by John and Armes [32] concluded that patient satisfaction was equivalent in the nurse-led clinic cohort compared with the medical-led clinic cohort and was, in some cases, preferred. However, the number in each group was not reported, and it is possible that patient satisfaction was related more to the decrease in wait times. It would likewise be difficult to attribute lifestyle changes to the clinic as patients were seen annually.
Physician-led
The included physician-led studies (n=4) presented comparisons of self-reported practices in survivorship follow-up [8] and clinician perceptions of survivorship follow-up [33] [34] [35] . A qualitative exploratory study by Chubak et al. [33] reported the views of clinicians and administrators (n=40) from ten integrated cancer centres. All respondents reported shared care was being practised. This was based on the assumption that all survivors have a PCP and despite respondents reporting a lack of standard approaches to sharing care between clinicians. Support for survivorship-specific care appeared lacking, with 22 % (n=9) observing it would not add to current care and may decrease care integration. The authors concluded that interviewing respondents from sites without survivorship care would give an unbiased account. However, there may have been a lack of awareness related to the benefits of survivorship care.
Dicicco-Bloom and Cunningham [8] qualitatively assessed the feasibility of a shared care survivorship model with 21 primary care clinicians. The overall perception was that primary carers are already involved in survivor follow-up, despite poor information provision from specialists. They perceived electronic medical records are often inaccessible. The authors further concluded survivorship care plan research is limited. PCPs felt excluded once patients entered the hospital system, especially when follow-up extended well past treatment to healthy patients with no recurrent cancer. This was reflected in the study by Greenfield et al. [35] who reported the views of clinicians (n=475) regarding long-term follow-up and found only 5 % (n=14) of haematology cancer survivors are discharged after 2 years, and only 42 % (n=45 lymphoma) and 32 % (n=10 leukaemia) are discharged after 5 years. This finding may be explained by the complex and ongoing late effect sequelae in haematology patients and their expectation of long-term specialist follow-up. Although respondent numbers were not reported, it was perceived that long-term specialist follow-up gave survivors false reassurance and perpetuated the illness role. Whereas the PCP-led model was perceived as normalising the survivors' experience, with a corresponding increase in comorbid disease management. The authors concluded by proposing a risk stratification process whereby low-risk survivors are transitioned early to PCP and high-risk survivors stay within the hospital model or become part of a shared care model supported by survivorship care plans. Frew et al. [34] studied survivor (n=626) and clinican (n= 2302) views on different models of care. Respondents could choose from a number of follow-up models but were not asked if they would reject a particular model. What was evident in the study by Frew et al. [34] was specialist follow-up, which was the most experienced by survivors (84 % n=528) and clinicians (95 % n=2167). However, specialists who had experienced non-specialist models of follow-up (60 % n= 819) preferred this model over all others including specialistled (87 %).
Discussion
Deciding upon a model of survivorship follow-up care for haematology cancer survivors is difficult due to the considerable variability between the types of haematological cancers, range of treatment regimens, and long-term and late effects that impact the survivorship phase of the cancer continuum [17] . For haematology cancer survivors, different models have been proposed and utilised. However, we are unable to determine the best or the most appropriate model. This finding is consistent with those of Campbell et al. [36] , reporting that no model was identified as better than any others. The reasons for these findings are that most of the articles were not evaluative in nature and do not allow comparison. Patients who have only received a single model of care would not be able to comment on potential benefits of other models of care; therefore, further research in understanding survivors' perspectives of follow-up care is required.
The transition of survivor care to the PCP requires PCP willingness. A study involving PCP views that reported the willingness to accept exclusive care for lymphoma patients was 3 years after treatment completion [37] . This may be due to the complex nature and length of the treatment regimens [15] and a lack of tumour specific follow-up protocols used by haematologists [35] . With a lack of guidance and comprehensive information communicated from the haematologist [8, 35] , PCPs may be reluctant to accept exclusive care of what they perceive as complex and 'high risk' patients [37] . Shared care may be more satisfactory to haematologists, survivors, and PCPs as it encompasses the strengths and expertise of providers from more than one discipline. As a study of follow-up care providers has reported, a high proportion of survivors are followed up by multiple providers [38] . Therefore, it is important that good coordination and communication is in place to reduce the possibility of either incomplete or duplication of services between multiple providers. Cooper et al. [27] proposed that patients' transition into survivorship phase and out to primary care through specialist nurses so that monitoring for recurrence, psychosocial needs, and health promotion are addressed and communicated to survivors and health care providers. This too has implications with John and Armes [32] who demonstrated that increased nurse workload occurred with patients utilising telephone contact between the scheduled clinic visits.
Establishing survivorship care provision will require careful planning and robust prospective evaluations. It is important to note that coordinated survivorship care interventions are complex interventions [39] and can be resource intensive, requiring robust evaluations using patient and system outcomes. This integrative review identified the three models of care: physician-led, nurse-led, and shared care models. Ultimately, high-quality pragmatic RCTs are required to test the effectiveness of these models. There is an urgent need for health research funders to understand the need for good survivorship cancer care and fund the development and evaluation of the effects of various models of survivorship care.
To the best of our knowledge, this review is the first that examines the characteristics, resources required, and effectiveness of survivorship care models specifically for patients with haematological cancer. A number of limitations of this review are acknowledged. The search revealed only a relatively small number of articles that met the inclusion criteria. Furthermore, the variation of study methodology, range of measures, populations, and follow-up approaches made it difficult to compare models of care and enabled only tentative conclusions [31, 32] . Additionally, short-term follow-up or the timing of interventions may have been insufficient to report whether different models have impacted survivorship care. Finally, an inherent bias in interpretation might be due to the evaluator.
Conclusion
There is a paucity of effectiveness research related to haematology cancer survivors and specifically models of survivorship care in this cohort. Shared care models have been suggested as an alternative to exclusive specialist care. For shared care to work effectively, ongoing communication channels need to be established and maintained. Nurse-led models have been proposed as another feasible model, where a specialist nurse intervenes directly and acts as the conduit between patient, hospital-based treatment team, and PCP. However, more research is needed to define how these models should be best configured and evaluated for their effectiveness. For future development, a haematology-specific survivor-based needs assessment tool, individualised treatment summary and survivorship care plan would be integral. These would assist in guiding survivor-centred screening, health promotion, and identification of needs to be monitored and managed. This approach may address many of the barriers that have been postulated.
Future research will need to account for increasing cancer incidence and survival rates, making extensive specialist follow-up care more difficult to maintain for new patients and survivors. To provide quality survivorship care, new and innovative models of haematology survivorship follow-up are required which address the need for long-term follow-up that accounts for potential late treatment effects, risks of secondary cancers, development of treatment-related co-morbid conditions, and psychosocial well-being. This review revealed a lack of high-quality evidence suggesting the effectiveness of any single model of care. A well-designed pragmatic randomised controlled trial, assessing patient and system outcomes including costs, is required to inform clinical practice.
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